Accordingly, multivariate survival analysis shows that ovarian cancer patients characterized by low NKX3-2 and active P53 display better clinical outcomes, which could be related to the sensitization of cancer cells to anticancer therapy and/or P53-induced mitigation of cancer aggressiveness. Here, TP53 is linked to ovarian carcinoma.